Siemens' PET/CT system receives FDA clearance
Siemens Healthcare has received 510(k) clearance from the FDA for the Biograph Horizon PET/CT system, which enables physicians to visualize small lesions early.
The system’s 4 mm LSO crystals scintillate faster and have a higher light output than BGO crystals, resulting in high resolution and better image quality, and enabling Time-of-Flight acquisition. Biograph Horizon’s capabilities will be particularly helpful for lung cancer detection, according to the company, since more than half of lung cancer patients are diagnosed at a late stage and have an increased likelihood of distant metastasis.
The Biograph Horizon is the smallest PET/CT system with the lowest power requirements, according to Siemens. It also offers automated manual tasks and protocol-based exams. The system also includes technologies such as gentle system warm-up and automatic standby that extend the system’s economic life in addition to reducing power consumption.
“More than 65 percent of healthcare institutions in the U.S. that are planning to purchase a new PET/CT system in the near future will be either replacing such a system or adding an additional unit,” says Mario Zeiss, vice president, Global Marketing and Sales, Siemens Healthcare, Molecular Imaging. “Biograph Horizon’s premium PET/CT technology and small footprint make it ideal for this market. The system’s versatility and scalability helps providers serve a broader mix of patients and expand into new service lines, creating competitive advantage and new opportunities for growth.”
Editor
Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.